Deepak R. Jadon
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients With Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations
R. Jadon, Deepak; Corp, Nadia; Van Der Windt, Danielle; C. Coates, Laura; R. Soriano, Enrique; Kavanaugh, Arthur; Raine, Tim; Rieder, Florian; Siebert, Stefan; Zummer, Michel; Schwartzman, Sergio; T. Rosenbaum, James; Michelsen, Brigitte; Laxminarayan, Ramasharan; Wu, Dongze; Gupta, Latika; Ng, Beverly; Jethwa, Hannah; De Windt, Nick; Gudu, Tania; Hutton, Joseph; O'Sullivan, Denis; M. Luchetti, Michele; Stoll, Matthew; A. Singh, Jasvinder; Peluso, Rosario; Rademacher, Judith; Elaine Husni, M.
Nadia Corp email@example.com
Danielle Van Der Windt firstname.lastname@example.org
Laura C. Coates
Enrique R. Soriano
James T. Rosenbaum
Nick De Windt
Michele M. Luchetti
Jasvinder A. Singh
M. Elaine Husni
Objective: Several advanced therapies have been licensed across the related conditions of psoriatic arthritis (PsA), Crohn disease (CD), ulcerative colitis (UC), and noninfectious uveitis. We sought to summarize results from randomized controlled trials (RCTs) investigating the efficacy and safety of advanced therapies for these related conditions in patients with PsA.
Methods: We updated the previous systematic search conducted in 2013 with literature reviews of MEDLINE, Embase, and the Cochrane Library (from February 2013 to August 2020) on this subject; only those new studies are presented here. The quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.
Results: The number of RCTs meeting eligibility criteria were 12 for CD, 15 for UC, and 5 for uveitis. The tumor necrosis factor inhibitor (TNFi) class appears to be efficacious and safe across CD, UC, and uveitis, with the exception of etanercept. Interleukin 12/23 inhibitors (IL-12/23i) are efficacious for CD and UC. Phase II and III RCTs of Janus kinase inhibitors (JAKi) and IL-23i in CD and UC are promising in terms of efficacy and safety. IL-17i must be used with great caution in patients with PsA at high risk of inflammatory bowel disease (IBD). RCTs in uveitis have mainly studied adalimumab.
Conclusion: We have identified 32 recent RCTs in IBD and uveitis and updated recommendations for managing patients with PsA and these related conditions. A multispecialty approach is essential to effectively, safely, and holistically manage such patients. Advanced therapies are not equally efficacious across these related conditions, with dosing regimens and safety varying.
|Journal Article Type||Article|
|Acceptance Date||Jun 28, 2022|
|Online Publication Date||Dec 1, 2022|
|Publication Date||Mar 1, 2023|
|Publicly Available Date||May 30, 2023|
|Journal||The Journal of Rheumatology|
|Publisher||Journal of Rheumatology|
|Peer Reviewed||Peer Reviewed|
|Keywords||GRAPPA; psoriasis; psoriatic arthritis|
Publisher Licence URL